| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2470 | 2016 |
| Trastuzumab emtansine for residual invasive HER2-positive breast cancer G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ... New England Journal of Medicine 380 (7), 617-628, 2019 | 2263 | 2019 |
| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1802 | 2019 |
| Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae, ... The lancet oncology 15 (8), 799-808, 2014 | 350 | 2014 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 260 | 2021 |
| Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain) P Cejas, E Casado, C Belda-Iniesta, J De Castro, E Espinosa, A Redondo, ... Cancer Causes & Control 15, 707-719, 2004 | 243 | 2004 |
| The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients S Leskelä, LJ Leandro-García, M Mendiola, J Barriuso, L Inglada-Pérez, ... Endocrine-related cancer 18 (1), 85-95, 2011 | 240 | 2011 |
| Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis A Isidoro, E Casado, A Redondo, P Acebo, E Espinosa, AM Alonso, ... Carcinogenesis 26 (12), 2095-2104, 2005 | 225 | 2005 |
| Safety and dose modification for patients receiving niraparib JS Berek, UA Matulonis, U Peen, P Ghatage, S Mahner, A Redondo, ... Annals of Oncology 29 (8), 1784-1792, 2018 | 174 | 2018 |
| Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions A Karam, JA Ledermann, JW Kim, J Sehouli, K Lu, C Gourley, ... Annals of Oncology 28 (4), 711-717, 2017 | 149 | 2017 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 110 | 2019 |
| Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial J Martin-Broto, S Stacchiotti, A Lopez-Pousa, A Redondo, D Bernabeu, ... The Lancet Oncology 20 (1), 134-144, 2019 | 110 | 2019 |
| Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial J Martin-Broto, N Hindi, G Grignani, J Martinez-Trufero, A Redondo, ... Journal for immunotherapy of cancer 8 (2), 2020 | 109 | 2020 |
| Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free … BJ Monk, A Poveda, I Vergote, F Raspagliesi, K Fujiwara, DS Bae, ... Gynecologic oncology 143 (1), 27-34, 2016 | 107 | 2016 |
| Angiogenesis and ovarian cancer C Gómez-Raposo, M Mendiola, J Barriuso, E Casado, D Hardisson, ... Clinical and Translational Oncology 11, 564-571, 2009 | 95 | 2009 |
| Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group … J Martin-Broto, AL Pousa, R de Las Peñas, X García del Muro, A Gutierrez, ... Journal of Clinical Oncology 34 (19), 2294-2302, 2016 | 79 | 2016 |
| Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study E Espinosa, JAF Vara, A Redondo, JJ Sanchez, D Hardisson, P Zamora, ... Journal of clinical oncology 23 (29), 7278-7285, 2005 | 78 | 2005 |
| LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced … MR Mirza, L Bjørge, F Marmé, RDP Christensen, M Gil-Martin, A Auranen, ... Annals of Oncology 31, S1160, 2020 | 68 | 2020 |
| Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial J Martin-Broto, J Cruz, N Penel, A Le Cesne, N Hindi, P Luna, DS Moura, ... The Lancet Oncology 21 (3), 456-466, 2020 | 68 | 2020 |
| LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial E Pujade-Lauraine, F Selle, G Scambia, B Asselain, F Marmé, ... Annals of Oncology 32, S1308-S1309, 2021 | 65 | 2021 |
